2024
The Alopecia Areata Severity and Morbidity Index (ASAMI) Study
Group A, Moussa A, Bennett M, Wall D, Meah N, York K, Bokhari L, Asfour L, Rees H, Abraham L, Asz-Sigall D, Basmanav F, Bergfeld W, Betz R, Bhoyrul B, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Dhurat R, Donovan J, Doroshkevich A, Eisman S, Farrant P, Ferrando J, Gadzhigoroeva A, Green J, Grimalt R, Harries M, Hordinsky M, Irvine A, Jolliffe V, Kaiumov S, King B, Lee J, Lee W, Li J, Lortkipanidze N, McMichael A, Mesinkovska N, Messenger A, Mirmirani P, Olsen E, Orlow S, Ovcharenko Y, Piraccini B, Pirmez R, Rakowska A, Reygagne P, Rudnicka L, Corralo D, Senna M, Shapiro J, Sharma P, Siliuk T, Starace M, Suchonwanit P, Takwale A, Tosti A, Vañó-Galván S, Visser W, Vogt A, Wade M, Yip L, Zhou C, Sinclair R. The Alopecia Areata Severity and Morbidity Index (ASAMI) Study. JAMA Dermatology 2024, 160: 341-350. PMID: 38324292, DOI: 10.1001/jamadermatol.2023.5869.Peer-Reviewed Original ResearchSurvey roundsTool scorePerspectives of patientsDisease impactDelphi study designHistory of anxietyImpaired quality of lifeQuality of lifeScalp hair lossIdentified various determinantsSeverity of Alopecia Tool scoreAssessment ScaleVideo conference meetingsGlobal Assessment ScaleStudy designImpaired qualitySurvey studyVideo conferencing softwareHair lossSuicidal ideationAA severityConference meetingsAlopecia areataSystemic treatmentDisease duration
2023
When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
King B, Shapiro J, Ohyama M, Egeberg A, Piraccini B, Craiglow B, Sinclair R, Chen Y, Wu W, Ding Y, Somani N, Dutronc Y. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. British Journal Of Dermatology 2023, 189: 666-673. PMID: 37708254, DOI: 10.1093/bjd/ljad253.Peer-Reviewed Original ResearchSevere alopecia areataBaricitinib-treated patientsPhase III trialsAlopecia areataResponder subgroupBaricitinib 4Hair regrowthIII trialsGrowth mixture modellingTreatment expectationsLate respondersEarly respondersBaseline disease characteristicsTreatment of adultsSALT scoreWeek 52Baseline characteristicsClinical outcomesDisease characteristicsTreatment allocationHair lossPatientsResponse subgroupsRespondersSubgroupsClinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Ko J, Mayo T, Bergfeld W, Dutronc Y, Yu G, Ball S, Somani N, Craiglow B. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata. JAMA Dermatology 2023, 159: 970-976. PMID: 37556146, PMCID: PMC10413213, DOI: 10.1001/jamadermatol.2023.2581.Peer-Reviewed Original ResearchConceptsSevere alopecia areataSALT scoreAlopecia areataWeek 76Response rateWeek 52Week 36Pooled analysisHair lossLong-term extension dataEyebrow hair lossProportion of patientsWeeks of therapyClinician-reported outcomesHigh response rateHair loss scoreSelective JanusAdult patientsClinical outcomesOutcome scoresHair regrowthClinical trialsMAIN OUTCOMETreatment doseBaricitinib41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata
Shapiro J, Ko J, Egeberg A, Somani N, Jedynak J, Torisu-Itakura H, Yu G, Lu N, Craiglow B. 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata. Journal Of The American Academy Of Dermatology 2023, 89: ab127. DOI: 10.1016/j.jaad.2023.07.511.Peer-Reviewed Original Research